<DOC>
	<DOCNO>NCT00729677</DOCNO>
	<brief_summary>RATIONALE : Learning often patient experience nausea vomit receive anti-vomiting medicine chemotherapy colorectal cancer may help doctor plan good treatment improve patient ' quality life . PURPOSE : This clinical trial study delay nausea vomit patient colorectal cancer receive standard anti-vomiting medicine first course chemotherapy .</brief_summary>
	<brief_title>Delayed Nausea Vomiting Patients With Colorectal Cancer Receiving Oxaliplatin</brief_title>
	<detailed_description>OBJECTIVES : - To assess prevalence delay nausea vomit patient colorectal cancer receive standard anti-emetic medication first course oxaliplatin-based chemotherapy regimen ( mFOLFOX6 FOLFOX7 ) . OUTLINE : This multicenter study . Patients undergo collection demographic , diagnostic , treatment data baseline . Patients complete Functional Living Index-Emesis ( FLIE ) questionnaire baseline prior first chemotherapy infusion 5-7 day . Patients also fill daily patient diary symptoms nausea vomiting , use medication prevent symptoms day 1-5 .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal cancer Currently receive OR schedule receive first course either follow chemotherapy regimen : mFOLFOX6 FOLFOX7 No clinical image evidence brain metastasis PATIENT CHARACTERISTICS : Able maintain diary complete standardize quality life questionnaire English PRIOR CONCURRENT THERAPY : See Disease Characteristics More 90 day since prior aprepitant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>colon cancer</keyword>
	<keyword>rectal cancer</keyword>
</DOC>